AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02957630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4/3 mg DRSP
Description: 15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Study NCT02957630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mcg EE/150 mcg LNG
Description: 30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Study NCT02957630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mcg EE/3 mg DRSP
Description: 20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Study NCT03270358 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling in arterioveinous fistula without stenosis
Description: Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session
Study NCT03270358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling in arterioveinous fistula with stenosis
Description: Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
Study NCT03516721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET
Study NCT03009864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tangshen Prescription
Description: The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
Study NCT03009864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangshen Prescription
Description: The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
Study NCT03009864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
Study NCT03610048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: samidorphan + buprenorphine administered sublingually
Study NCT02900430 — intervention group
Intervention type: OTHER
Intervention: Patients without antifungal prophylaxis
Description: Epidemiology data: clinical and biological informations collecting
Study NCT02900430 — intervention group
Intervention type: DRUG
Intervention: Patients with antifungal prophylaxis
Description: Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
Study NCT04510207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell)
Description: The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chia Oil
Description: Shake with 50 g Chia oil
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chia Oil
Description: Shake with 50 g Chia oil
Study NCT04510207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell)
Description: The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP
Study NCT04510207 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
Study NCT01340456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin treatment
Description: induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
Study NCT04033458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.
Study NCT01731561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Arm B)
Description: Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are > to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
Study NCT01731561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (Arm A)
Description: Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
Study NCT03009864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
Study NCT00898846 — intervention group
Intervention type: DRUG
Intervention: UFT adjuvant chemotherapy
Description: UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
Study NCT00775957 — intervention group
Intervention type: PROCEDURE
Intervention: FLT-PET scan
Description: imaging scan
Study NCT00775957 — intervention group
Intervention type: PROCEDURE
Intervention: FDG-PET scan
Description: imaging scan
Study NCT01745016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01745016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Study NCT02974634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ostomy self management training
Description: Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
Study NCT02974634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ostomy self management training
Description: Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given PO
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Butter
Description: Shake with 50 g Butter
Study NCT01876394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Shake with 50 g Butter
Study NCT04237402 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hair follicles sampling
Description: The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
Study NCT04134585 — intervention group
Intervention type: OTHER
Intervention: semi-structured interviews
Description: Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
Study NCT03587480 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TME+LLND
Description: patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
Study NCT03587480 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TME+nCRT
Description: patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
Study NCT04822857 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AMH
Description: The group was divided according to the level of Anti-Müllerian Hormone
Study NCT03529136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC
Description: Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
Study NCT00423618 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
Study NCT00423618 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
Study NCT02010437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Tetradecyl Sulphate (STS)
Study NCT02645006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 session workshop
Description: The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
Study NCT02645006 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 session workshop
Description: The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
Study NCT04147819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
Study NCT04147819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
Study NCT04008537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring gantry kV-CBCT combined with linear accelerator
Description: Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
Study NCT03978091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZACTAM
Description: A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
Study NCT03978091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime-Avibactam
Description: An antibacterial combination product containing ceftazidime and avibactam
Study NCT00650988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryospray Ablation
Description: Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
Study NCT00591331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad (the active ingredient in NatrOVA)
Description: This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
Study NCT00591331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01387763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
Study NCT01387763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
Study NCT01387763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrea
Description: Capsule Hydrea 500-2000 mg orally QD or BID
Study NCT03878888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 266 MG Per 20 ML Injection
Description: patients receive Exparel in bilateral TAP blocks for open abdomen surgery
Study NCT04636593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20\<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
Study NCT01708499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT03339024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin spray
Description: 6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
Study NCT03339024 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intranasal spray without oxytocin
Description: 6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
Study NCT02589340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Study NCT02589340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill
Study NCT02972801 — intervention group
Intervention type: PROCEDURE
Intervention: Testicular biopsy
Description: Testicular biopsy is performed to obtain testicular tissue for cryopreservation
Study NCT00638482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide
Study NCT02916589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Study NCT02916589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Study NCT03880734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
Study NCT03880734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
Study NCT04061265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml
Description: Local anesthetic agent
Study NCT04061265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride 2% and epinephrine 1:100000
Description: Local anesthetic agent
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT01935947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01935947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT01935947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT02896205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
Study NCT02896205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given matching placebo for 6 months
Study NCT02428426 — intervention group
Intervention type: OTHER
Intervention: endomicroscopy, targeted biopsy and 16s rRNA gene sequencing
Study NCT00603681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 4000
Description: powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
Study NCT00603681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 4000 with electrolytes
Description: granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
Study NCT03807089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pediatric Colonoscope
Study NCT03807089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short-Turn Radius Colonoscope
Study NCT03289754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPoly XE tibial insert with ConforMIS iTotal KRS
Description: The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
Study NCT02328872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular testing for HPV
Description: Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
Study NCT02328872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Based Cytology
Description: The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
Study NCT01603654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium picosulphate magnesium citrate
Description: Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
Study NCT01603654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-volume PEG -ascorbic acid
Description: THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
Study NCT04556253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration.
Study NCT00364325 — intervention group
Intervention type: OTHER
Intervention: Acute Decompensated Heart Failure
Description: Standard of Care